to form Scipher Medicine Corporation
- Chemomab holders expected to own about 32% of the combined company and receive contingent value rights.
- Transaction structure includes a concurrent $30 million financing alongside the all-stock merger agreement.
- Combined company will focus on advancing nebokitug into an AI-guided Phase 2 rheumatoid arthritis trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.